High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: No evidence for efficacy

Clinical and Experimental Rheumatology

Volumn 14, Issue 6, 1996, Pages 657-660

  Maksymowych, W P ^a,b   Avina Zubieta A ^a   Luong, M ^a   Russell, A S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA ENVIRONMENT AND PARKS   (Canada)

Author keywords

immunoglobulins; rheumatoid arthritis; tumor necrosis factor

Indexed keywords

IMMUNOGLOBULIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CASE REPORT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT FAILURE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL ASSAY; BLOOD CELL COUNT; BLOOD SEDIMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030442286     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. JORDAN SC: Intravenous gamma-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 1989; 53: S164-S169.
2. GAJDOS PH, OUTIN H, ELKHARRAT D: High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 1: 406-7.
3. MUSCAT C, BERTOTTO A, ERCOLANI R, BISTONI O, AGEA E, CESAROTTI M, FIORUCCI G, SPINOZZI F, GERLIR: Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis 1995; 54: 382-5.
4. TUMIATI B, CASOLI P, VENEZIANI M, RINALDI G: High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 1126-33.
5. ACHIRON A, MARGALIT R, HERSHKOVIZ R, MARKOVITS D, RESHEF T, MELAMED E, COHEN IR, LIDER O: Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. J Clin Invest 1994; 93: 600-5.
6. BRENNAN FM. FIELD M, CHU CQ, FELDMANN M, MAINI RN: Cytokine expression in rheumatoid arthritis. Br J Rheumatol 1991; (Suppl. 1) 30: 76-80
7. . 7. WOOLEY PH, DUTCHER J, WIDMER MB, GILLIS S: Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on Type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602-7.
8. ELLIOTT MJ, MAINI RN, FELDMANN M, LONG-FOX A, CHARLES P, KATSIKIS P, BRENNAN F, WALKER J, BIJL H, GHRAYEB J, WOODY JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993; 36: 1681-90.
9. ARNETT FC, EDWORTHY SM, BLOCK DA, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
10. BEMELMANS MHA, GOUMA DJ, BUURMAN WA: LPS-induced sTNF-receptor release in vivo in a murine model. J Immunol 1993; 151: 5554-62.
11. BARRERA P, BOERBOOMS AMT, DEMACKER PNM, VAN DE PUTTE LBA, GALLATI H, VAN DER MEER JWM: Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of single dose methotrexate. Br J Rheumatol 1994; 33: 1017-24.
12. BECKER H, MITROPOULOU G, HELMKE K: Immuno-modulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin. Klin Wochenschr 1989; 67: 286-90.
13. LAM L, WHITSETT CF, MCNICHOLL JM, HODGE TW, HOOPER J: Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342: 678.
14. EMERY P, SPATH P, AFFENTRANGER P, SCHWARTZ HA, GOUGH A: A placebo controlled double-blind study of high dose intravenous immunoglobulin therapy in patients with early rheumatoid arthritis. Arthritis Rheum 1993; 557: 113.
15. SILVERMAN ED, CAWKWELL GD, LOVELL DJ, LAXER RM, LEHMAN TJA, PASSO MH, ZEMEL LS, GIANNINI EH: Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. J Rheumatol 1994; 21: 2353-8.